Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05347979 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushing Syndrome
Neoplasms

Interventions

DRUG: Dabigatran Etexilate
DRUG: Relacorilant

Sponsor

Corcept Therapeutics